- Adjusted EPS for 2Q 2024 was $2.34, beating the estimate of $2.18.
- Reported EPS for the quarter was 78 cents.
- Sales for the quarter were $10.16 billion, below the estimate of $10.75 billion.
- Phosphate net sales amounted to $394 million.
- Adjusted Ebitda for the quarter was $2.24 billion, slightly above the estimate of $2.2 billion.
- Phosphate Adjusted Ebitda was $88 million, missing the estimate of $134.8 million.
- Ken Seitz, Nutrien’s President and CEO, stated the company benefited from better Retail margins, higher fertilizer sales volumes, and lower operating costs in the first half of 2024.
- Crop input demand remains strong, prompting an increase in the full-year outlook for global potash demand.
- Nutrien’s stock ratings include 16 buys, 5 holds, and 4 sells.
A look at Nutrien Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Nutrien is positioned well for the long term. With solid scores in Value, Dividend, and Growth factors, Nutrien is demonstrating strength in its financial fundamentals and potential for future expansion. These scores suggest that Nutrien is a company that offers good value to investors, provides attractive dividend returns, and shows promising growth prospects.
However, Nutrien’s lower scores in Resilience and Momentum indicate some areas of caution. The Resilience score suggests that the company may face challenges in adapting to unforeseen economic or market conditions, while the Momentum score indicates a moderate level of market performance compared to its peers. Overall, Nutrien’s diversified business model as a provider of crop inputs and services for various industries positions it well for sustainable growth in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
